Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965560 | 1.00 | HTR2C (0.34) | HTR2CMAPK1HTR2AMTNR1AMTNR1B | |
| SCHEMBL4056071 | 0.81 | HSD17B10 (0.39) | MAPK1HPGDKDM4EALDH1A1 | |
| SCHEMBL3966091 | 0.75 | MMP2 (0.42) | HPGDKDM4EALDH1A1 | |
| SCHEMBL6197028 | 0.63 | MAPT (0.45) | HTR2CHTR2AKDM4EALDH1A1 | |
| SCHEMBL3965557 | 0.60 | HTR2C (0.69) | HTR2CHTR2AMTNR1AMTNR1BHTR2B | |
| SCHEMBL14559577 | 0.56 | ALDH1A1 (0.55) | MAPK1ALDH1A1 | |
| SCHEMBL29592501 | 0.56 | MAPT (0.41) | HTR2CMAPK1HTR2AHPGDHTR2B | |
| Bromide SCHEMBL29228836 | 0.55 | MAPT (0.40) | HTR2CMAPK1HTR2AHPGDHTR2B | |
| SCHEMBL4347043 | 0.55 | MAOB (0.54) | HPGDKDM4EALDH1A1 | |
| SCHEMBL19086030 | 0.55 | MAOB (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476687-B2 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2009-01-13 | — | — | US | disclosed |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20070135430-A1 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2007-06-14 | — | — | US | disclosed |
| WO-2005053688-A1 | SUBSTITUTED FURO[2,3-G] INDAZOLES FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135430-A1 | Substituted furo[2,3-g]indazoles for the treatment of glaucoma | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885MAPK1 3057/4885HTR2A 1195/4885 |
| US-20090012291-A1 | SUBSTITUTED FURO[2,3-g]INDAZOLES FOR THE TREATMENT OF GLAUCOMA | PTGIS, PTGIR, PTGS2 | HTR2C 646/4885MAPK1 3057/4885HTR2A 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.